WallStSmart

CSX Corporation (CSX)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CSX Corporation generates 339% more annual revenue ($14.15B vs $3.22B). CSX leads profitability with a 21.5% profit margin vs 16.9%. CSX appears more attractively valued with a PEG of 2.09. WST earns a higher WallStSmart Score of 67/100 (B-).

CSX

Buy

65

out of 100

Grade: C+

Growth: 4.7Profit: 8.0Value: 6.7Quality: 3.5
Piotroski: 2/9Altman Z: 1.20

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CSXUndervalued (+44.4%)

Margin of Safety

+44.4%

Fair Value

$74.29

Current Price

$44.83

$29.46 discount

UndervaluedFair: $74.29Overvalued
WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CSX5 strengths · Avg: 9.0/10
Operating MarginProfitability
36.2%10/10

Strong operational efficiency at 36.2%

Market CapQuality
$83.30B9/10

Large-cap with strong market position

Return on EquityProfitability
23.7%9/10

Every $100 of equity generates 24 in profit

Profit MarginProfitability
21.5%9/10

Keeps 22 of every $100 in revenue as profit

EPS GrowthGrowth
26.5%8/10

Earnings expanding 26.5% YoY

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

CSX4 concerns · Avg: 3.8/10
PEG RatioValuation
2.094/10

Expensive relative to growth rate

P/E RatioValuation
27.5x4/10

Moderate valuation

Revenue GrowthGrowth
1.7%4/10

1.7% revenue growth

Debt/EquityHealth
1.433/10

Elevated debt levels

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : CSX

The strongest argument for CSX centers on Operating Margin, Market Cap, Return on Equity. Profitability is solid with margins at 21.5% and operating margin at 36.2%.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : CSX

The primary concerns for CSX are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

CSX profiles as a value stock while WST is a growth play — different risk/reward profiles.

CSX carries more volatility with a beta of 1.24 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

CSX generates stronger free cash flow (729M), providing more financial flexibility.

Bottom Line

WST scores higher overall (67/100 vs 65/100), backed by strong 16.9% margins and 21.0% revenue growth. CSX offers better value entry with a 44.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CSX Corporation

INDUSTRIALS · RAILROADS · USA

CSX Corporation is an American holding company focused on rail transportation and real estate in North America, among other industries. Based in Richmond, Virginia, USA after the merger, in 2003 the CSX Corporation headquarters moved to Jacksonville, Florida.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?